Non-steroidal anti-inflammatory drugs target the pro-tumorigenic extracellular matrix of the postpartum mammary gland

International Journal of Developmental Biology

Volumn 55, Issue 7-9, 2011, Pages 745-755

  O'Brien, Jenean ^a   Hansen, Kirk ^a   Barkan, Dalit ^b   Green, Jeffrey ^c   Schedin, Pepper ^a,d  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF HAIFA   (Israel)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d University of Colorado Cancer Center   (United States)

Author keywords

3D culture; Breast cancer; Involution; NSAID; Proteomics; Tenascin C

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 2; IBUPROFEN; TENASCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CELL CULTURE; CONTROLLED STUDY; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN CELL; INVOLUTION; MAMMARY GLAND; MOUSE; NONHUMAN; NULLIPARA; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEOMICS; PUERPERIUM; RAT; TUMOR CELL; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARCINOGENS; CELL LINE, TUMOR; CYCLOOXYGENASE 2; EXTRACELLULAR MATRIX; FEMALE; HUMANS; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; POSTPARTUM PERIOD; PREGNANCY; RATS; RATS, SPRAGUE-DAWLEY; TENASCIN;

EID: 82555196967     PISSN: 02146282     EISSN: None     Source Type: Journal    
DOI: 10.1387/ijdb.113379jo     Document Type: Article

References (58)

1. ARIAS OR, MARQUEZ-OROZCO MC (2006). Aspirin, acetaminophen, and ibuprofen: their effects on orthodontic tooth movement. Am J Orthod Dentofacial Orthop 130: 364-370.
2. BARKAN D, KLEINMAN H, SIMMONS JL, ASMUSSEN H, KAMARAJU AK, HOENORHOFF MJ, LIU ZY, COSTES SV, CHO EH, LOCKETT S, KHANNA C, CHAMBERS AF, GREEN JE (2008). Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. Cancer Res. 68: 6241-6250.
3. BARKAN D, EL TOUNY LH, MICHALOWSKI AM, SMITH JA, CHU I, DAVIS AS, WEBSTER JD, HOOVER S, SIMPSON RM, GAULDIE J, GREEN JE (2010). Metastatic growth from dormant cells induced by a col-I-enriched fibrotic environment. Cancer Res. 70: 5706-5716.
4. BAUMAN KA, WETTLAUFER SH, OKUNISHI K, VANNELLA KM, STOOLMAN JS, HUANG SK, COUREY AJ, WHITE ES, HOGABOAM CM, SIMON RH, TOEWS GB, SISSON TH, MOORE BB, PETERS-GOLDEN M. (2010). The antifibrotic effects of plasminogen activation occur via prostaglandin E2 synthesis in humans and mice. J Clin Inv 120: 1950-1960.
5. BEMIS LT, SCHEDIN P (2000). Reproductive state of rat mammary gland stroma modulates human breast cancer cell migration and invasion. Cancer Res. 60: 3414-3418.
6. BISSELL MJ, AGGELER J (1987). Dynamic reciprocity: how do extracellular matrix and hormones direct gene expression? Prog Clin Biol Res 249: 251-262.
7. CONKLIN MW, EICKHOFF JC, RICHING KM, PEHLKE CA, ELICEIRI KW, PROVENZANO PP, FRIEDL A, KEELY PJ (2011). Aligned collagen is a prognostic signature for survival in human breast carcinoma. Am. J. Pathology 178: 1221-1232.
8. DEBNATH J, MUTHUSWAMY SK, BRUGGE JS (2003). Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30: 256-268.
9. DENG S, DENG PY, JIANG JL, YE F, YU J, YANG TL, DENG HD, LI YJ (2004). Aspirin protected against endothelial damage induced by LDL: role of endogenous NO synthase inhibitors in rats. Acta Pharmacol. Sinica 25: 1633-1639.
10. DUFORT CC, PASZEK MJ, WEAVER VM (2011). Balancing forces: architectural control of mechanotransduction. Nat Rev Mol Cell Biol 12: 308-319.
11. ELDER DJ, PARASKEVA C (1998). COX-2 inhibitors for colorectal cancer. Nat Med 4: 392-393.
12. GEFFROTIN C, HORAK V, CRECHET F, TRICAUD Y, LETHIAS C, VINCENT-NAULLEAU S, VIELH P (2000). Opposite regulation of tenascin-C and tenascin-X in MeLiM swine heritable cutaneous malignant melanoma. Biochim Biophys Acta 1524: 196-202.
13. HANCOX RA, ALLEN MD, HOLLIDAY DL, EDWARDS DR, PENNINGTON CJ, GUTTERY DS, SHAW JA, WALKER RA, PRINGLE JH, JONES JL (2009). Tumour-associated tenascin-C isoforms promote breast cancer cell invasion and growth by matrix metalloproteinase-dependent and independent mechanisms. Breast Cancer Res 11: R24.
14. HANSEN KC, KIEMELE L, MALLER O, O'BRIEN J, SHANKAR A, FORNETTI J, SCHEDIN P (2009). An in-solution ultrasonication-assisted digestion method for improved extracellular matrix proteome coverage. Mol Cell Proteomics 8: 1648-1657.
15. HASLAM SZ, WOODWARD TL (2001). Reciprocal regulation of extracellular matrix proteins and ovarian steroid activity in the mammary gland. Breast Cancer Res 3: 365-372.
16. HATTAR R, MALLER O, MCDANIEL S, HANSEN KC, HEDMAN KJ, LYONS TR, LUCIA S, WILSON RS, JR., SCHEDIN P (2009). Tamoxifen induces pleiotrophic changes in mammary stroma resulting in extracellular matrix that suppresses transformed phenotypes. Breast Cancer Res 11: R5.
17. HOLMES MD, CHEN WY, LI L, HERTZMARK E, SPIEGELMAN D, HANKINSON SE (2010). Aspirin intake and survival after breast cancer. J Clin Oncol 28: 1467-1472.
18. IAVNILOVITCH E, GRONER B, BARASH I (2002). Overexpression and forced activation of stat5 in mammary gland of transgenic mice promotes cellular proliferation, enhances differentiation, and delays postlactational apoptosis. Mol Cancer Res 1: 32-47.
19. IOACHIM E, CHARCHANTI A, BRIASOULIS E, KARAVASILIS V, TSANOU H, ARVANITIS DL, AGNANTIS NJ, PAVLIDIS N (2002). Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. Eur J Cancer 38: 2362-2370.
20. JONES PL, JONES FS, ZHOU B, RABINOVITCH M (1999). Induction of vascular smooth muscle cell tenascin-C gene expression by denatured type I collagen is dependent upon a beta3 integrin-mediated mitogen-activated protein kinase pathway and a 122-base pair promoter element. J Cell Sci 112(Pt 4): 435-445.
21. JONES PL (2001). Extracellular matrix and tenascin-C in pathogenesis of breast cancer. Lancet 357: 1992-1994.
22. KINUGASA S, SMITH E, DREW PA, WATSON DI, JAMIESON GG (2004). Aspirin and indomethacin for the prevention of experimental port-site metastases. Surgical Endoscopy 18: 834-838.
23. KRAUSE S, MAFFINI MV, SOTO AM, SONNENSCHEIN C (2008). A novel 3D in vitro culture model to study stromal-epithelial interactions in the mammary gland. Tissue Engineering 14: 261-271.
24. KWAN ML, HABEL LA, SLATTERY ML, CAAN B (2007). NSAIDs and breast cancer recurrence in a prospective cohort study. Cancer Causes Control 18: 613-620.
25. LACY CF, ARMSTRONG, LORA L., GOLDMAN, MORTON P., AND LANCE, LEONARD L. (2007). Drug Information Handbook: A Comprehensive Resource for All Clinicians and Healthcare Professionals, 15 edn. Hudson, OH: Lexi-Comp.
26. LEVENTAL KR, YU H, KASS L, LAKINS JN, EGEBLAD M, ERLER JT, FONG SF, CSISZAR K, GIACCIA A, WENINGER W, YAMAUCHI M, GASSER DL, WEAVER VM (2009). Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139: 891-906.
27. LEVY P, RIPOCHE H, LAURENDEAU I, LAZAR V, ORTONNE N, PARFAIT B, LEROY K, WECHSLER J, SALMON I, WOLKENSTEIN P, DESSEN P, VIDAUD M, VIDAUD D, BIECHE I (2007). Microarray-based identification of tenascin C and tenascin XB, genes possibly involved in tumorigenesis associated with neurofibromatosis type 1. Clin Cancer Res 13: 398-407.
28. LOPEZ-DE LEON A, ROJKIND M (1985). A simple micromethod for collagen and total protein determination in formalin-fixed paraffin-embedded sections. J Histochem Cytochem 33: 737-743.
29. LUND LR, ROMER J, THOMASSET N, SOLBERG H, PYKE C, BISSELL MJ, DANO K, WERB Z (1996). Two distinct phases of apoptosis in mammary gland involution: proteinase-independent and-dependent pathways. Development (Cambridge, England) 122: 181-193.
30. LYONS TR, SCHEDIN PJ, BORGES VF (2009). Pregnancy and breast cancer: when they collide. J. Mammary Gland Biol. Neoplasia 14: 87-98.
31. LYONS TR, O'BRIEN J, BORGES V, CONKLIN MW, KEELY PJ, ELICEIRI KW, MARUSYK A, TAN AC, SCHEDIN P (2011). Postpartum mammary gland involution drives progression of ductal carcinoma in situ through collagen and COX-2. Nature Med 17: 1109-1115.
32. MAO JR, TAYLOR G, DEAN WB, WAGNER DR, AFZAL V, LOTZ JC, RUBIN EM, BRISTOW J (2002). Tenascin-X deficiency mimics Ehlers-Danlos syndrome in mice through alteration of collagen deposition. Nat Genet 30: 421-425.
33. MCDANIEL SM, RUMER KK, BIROC SL, METZ RP, SINGH M, PORTER W, SCHEDIN P (2006). Remodeling of the mammary microenvironment after lactation promotes breast tumor cell metastasis. Am. J. Pathology 168: 608-620.
34. MENOZZI A, POZZOLI C, GIOVANNINI E, SOLENGHI E, GRANDI D, BONARDI S, BERTINI S, VASINA V, CORUZZI G (2006). Intestinal effects of nonselective and selective cyclooxygenase inhibitors in the rat. Eur. J. Pharmacol. 552: 143-150.
35. NAUMOV GN, MACDONALD IC, WEINMEISTER PM, KERKVLIET N, NADKARNI KV, WILSON SM, MORRIS VL, GROOM AC, CHAMBERS AF (2002). Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Res. 62: 2162-2168.
36. O'BRIEN J, SCHEDIN P (2009). Macrophages in breast cancer: do involution macrophages account for the poor prognosis of pregnancy-associated breast cancer? J. Mammary Gland Biol. Neoplasia 14: 145-157.
37. O'BRIEN J, LYONS T, MONKS J, LUCIA MS, WILSON RS, HINES L, MAN YG, BORGES V, SCHEDIN P (2010a). Alternatively activated macrophages and collagen remodeling characterize the postpartum involuting mammary gland across species. Am. J. Pathology 176: 1241-1255.
38. O'BRIEN J, FORNETTI J, SCHEDIN P (2010b). Isolation of mammary-specific extracellular matrix to assess acute cell-ECM interactions in 3D culture. J. Mammary Gland Biol. Neoplasia 15: 353-364.
39. OREND G (2005). Potential oncogenic action of tenascin-C in tumorigenesis. Int. J. Biochem. Cell Biol. 37: 1066-1083.
40. OSKARRSON T, ACHARYYA S, ZHANG XH, VANHARANTA S, TAVAZOIE SF, MORRIS PG, DOWNEY RJ, MANOVA-TODOROVA K, BROQI E, MASSAGUE J (2011). Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nature Med 17: 867-874.
41. PROVENZANO PP, INMAN DR, ELICEIRI KW, KNITTEL JG, YAN L, RUEDEN CT, WHITE JG, KEELY PJ (2008). Collagen density promotes mammary tumor initiation and progression. BMC medicine 6: 11.
42. RILEY GP, HARRALL RL, CAWSTON TE, HAZLEMAN BL, MACKIE EJ (1996). Tenascin-C and human tendon degeneration. Am. J. Pathol. 149: 933-943.
43. SCHEDIN P, STRANGE R, MITRENGA T, WOLFE P, KAECK M (2000). Fibronectin fragments induce MMP activity in mouse mammary epithelial cells: evidence for a role in mammary tissue remodeling. J Cell Sci 113(Pt 5): 795-806.
44. SCHEDIN P, MITRENGA T, MCDANIEL S, KAECK M (2004a). Mammary ECM composition and function are altered by reproductive state. Molec. Carcinogenesis 41: 207-220.
45. SCHEDIN P, ECKEL-MAHAN KL, MCDANIEL SM, PRESCOTT JD, BRODSKY KS, TENTLER JJ, GUTIERREZ-HARTMANN A (2004b). ESX induces transformation and functional epithelial to mesenchymal transition in MCF-12A mammary epithelial cells. Oncogene 23: 1766-1779.
46. SCHEDIN P (2006). Pregnancy-associated breast cancer and metastasis. Nature Rev. 6: 281-291.
47. SCHEDIN P, KEELY PJ (2011). Mammary gland ECM remodeling, stiffness, and mechanosignaling in normal development and tumor progression. Cold Spring Harb Perspect Biol 3: a003228.
48. SHAW KR, WROBEL CN, BRUGGE JS (2004). Use of three-dimensional basement membrane cultures to model oncogene-induced changes in mammary epithelial morphogenesis. J. Mammary Gland Biol. Neoplasia 9: 297-310.
49. SMITH GH, SHARP R, KORDON EC, JHAPPAN C, MERLINO G (1995). Transforming growth factor-alpha promotes mammary tumorigenesis through selective survival and growth of secretory epithelial cells. Am. J. Pathol. 147: 1081-1096.
50. STENSHEIM H, MOLLER B, VAN DIJK T, FOSSA SD (2009). Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study. J Clin Oncol 27: 45-51.
51. TARASEVICIUTE A, VINCENT BT, SCHEDIN P, JONES PL (2010). Quantitative analysis of three-dimensional human mammary epithelial tissue architecture reveals a role for tenascin-C in regulating c-met function. Am. J. Pathol. 176: 827-838.
52. THUN MJ, NAMBOODIRI MM, HEATH CW, JR. (1991). Aspirin use and reduced risk of fatal colon cancer. New Engl. J. Med. 325: 1593-1596.
53. TREMBLE P, CHIQUET-EHRISMANN R, WERB Z (1994). The extracellular matrix ligands fibronectin and tenascin collaborate in regulating collagenase gene expression in fibroblasts. Molec. Biol. Cell 5: 439-453.
54. VOLLMER G (1994). Expression of tenascin during carcinogenesis and involution of hormone-dependent tissues. Biochem. Cell Biol. 72: 505-514.
55. WEAVER VM, PETERSEN OW, WANG F, LARABELL CA, BRIAND P, DAMSKY C, BISSELL MJ (1997). Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J. Cell Biol. 137: 231-245.
56. WILGUS TA, BERGDALL VK, TOBER KL, HILL KJ, MITRA S, FLAVAHAN NA, OBERYSZYN TM (2004). The impact of cyclooxygenase-2 mediated inflammation on scarless fetal wound healing. Am. J. Pathology 165: 753-761.
57. YUAN Y, NYMOEN DA, STAVNES HT, ROSNES AK, BJORANG O, WU C, NESLAND JM, DAVIDSON B (2009). Tenascin-X is a novel diagnostic marker of malignant mesothelioma. Am J Surg Pathol 33: 1673-1682.
58. ZENG Z, HINCAPIE M, PITTERI SJ, HANASH S, SCHALKWIJK J, HOGAN JM, WANG H, HANCOCK WS (2011). A Proteomics Platform Combining Depletion, Multi-lectin Affinity Chromatography (M-LAC), and Isoelectric Focusing to Study the Breast Cancer Proteome. Anal Chem 83: 4845-4854.